Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein ...

Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit ...

CEO Kim Kelderman reported that "our second quarter performance was largely in line with our expectations. Continued strength from our large pharma customers was offset by a soft yet improving biotech ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring ...

Merck KGaA, Darmstadt, Germany, and Bio-Techne announced they entered into a definitive agreement under which Merck KGaA will acquire Bio-Techne for $73 per share in cash. The transaction represents a ...

The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...

Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

A German company that provides products and services that accelerate drug development and manufacturing is set to acquire the Minneapolis-based group Bio-Techne, according to a news release posted ...